 | |
| Clinical data | |
|---|---|
| Other names | 2-PYI; 2-Pyrrolidinylindane; 1-(2-Indanyl)pyrrolidine; Compound 10j |
| Drug class | Stimulant |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C13H17N |
| Molar mass | 187.286 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Pyr-AI, also known as2-pyrrolidinylindane (2-PYI), is astimulantdrug of the2-aminoindane family.[1] It is theanalogue of2-aminoindane (2-AI) in which theamine has been replaced with apyrrolidine group.[1] The drug has been described as having strong and long-lastingamphetamine-like effects in rodents.[1][2] Other 2-aminoindanes like 2-AI itself andNM-2-AI are known to act aspotentmonoamine releasing agents andreuptake inhibitors.[3][4] Pyr-AI was first described in thescientific literature by 1973.[1][2]
A 'strong amphetamine-type activity' has been reported for the pyrrolidine derivative of 2-AI (26, Fig. 11.10) [41] and 'a long duration' of activity was observed at the 10mg/kg dose in mice. Details about the procedure were not provided but neuropharmacological screenings were based on observational methods [48]. A piperidine derivative (27, PIP-AI), on the other hand, showed analgesic properties comparable to meperidine [41].
 | Thispsychoactive drug-related article is astub. You can help Wikipedia byexpanding it. |
